E’ UTILE LA CHEMIOTERAPIA NEODIUVANTE PRIMA DELLA RESEZIONE DEL CANCRO DEL PANCREAS? UN OTTIMO EDITORIALE COMMENTA TUTTE LE EVIDENZE VS IL NORPACT-1 (vedi in bacheca). DA “Lancet Gastroenterol Hepatol “
The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned David Henault et al. Neoadjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma is not currently recommended as standard practice but can be considered for patients at high risk (eg, high CA19-9, systemic symptoms, or nodal disease) or in a clinical trial. The PRODIGE24/CCTG-PA.6 adjuvant trial demonstrated…

